Tyra Biosciences 的收益超出预期，新投资者 EntryPoint Capital 的大量涌入。 Tyra Biosciences beats earnings estimates, sees influx from new investor EntryPoint Capital.

Tyra Biosciences是一家为FGFR生物学研制精密药品的生物技术公司,报告季度收入比预期的要好,EPS(0.43美元),而估计是0.48美元。 Tyra Biosciences, a biotech company developing precision medicines for FGFR biology, reported better-than-expected quarterly earnings, with EPS of ($0.43) against an estimated ($0.48). 该公司的市场上限为4.9439亿美元,“Buy”评级为30.83美元,目标价格为30.83美元。 The company has a market cap of $494.39 million and a "Buy" rating with a target price of $30.83. 最近,IncentPoint Capital LLC在该公司投资,购买了价值253 000美元的股票。 Recently, EntryPoint Capital LLC invested in the company, purchasing $253,000 worth of shares.